House committee backs bill to expand sickle cell care, require fertility‑preservation coverage

The House Committee on Financial Services reported House Bill No. 4554, "An Act to improve sickle cell care," recommending the bill "ought to pass." The petitioners listed are Bud L. Williams and David M. Rogers; the committee filing is signed "For the committee, James M. Murphy."

The bill would require the Division of Medical Assistance to apply to the Centers for Medicare & Medicaid Services for a Medicaid waiver or state plan amendment so MassHealth could provide coverage for "standard fertility preservation services" to qualified enrollees whose treatments may cause iatrogenic infertility. The text defines standard fertility preservation services to include the retrieval and storage of two complete oocyte cycles and the collection and storage of two sperm samples. The bill sets reporting requirements for the division on state spending attributable to that coverage, with the first report due November 1, 2025, and then every third year.

Separately, the bill would require health insurance policies subject to specified Massachusetts statutes to cover medically necessary fertility preservation services when a necessary medical treatment may directly or indirectly cause infertility. The provision prohibits insurers from discriminating based on expected length of life, disability, quality of life or personal characteristics such as age, sex, sexual orientation or marital status.

The Department of Public Health would be required to establish a Statewide Steering Committee on Sickle Cell Disease. The committee’s membership categories include representatives of the Massachusetts Sickle Cell Disease Association, medical professionals from major treatment centers, community health workers, social workers, representatives appointed by the Governor and commissioner, and patients and parents. The steering committee’s duties include creating institution and community partnerships, developing educational materials, identifying funding sources, studying standards of multidisciplinary care, and establishing subcommittees as needed.

The bill creates a sickle cell disease detection and education program in the Department of Public Health to promote screening and early detection, run a statewide public education campaign, and provide grants to approved organizations and community-based organizations for screening, counseling, referral and outreach. Approved organizations would be required to submit annual reports to the commissioner; the commissioner must submit an annual report to the governor and legislature.

The bill directs the commissioner to establish and maintain a reporting system and registry for sickle cell disease and its variants. Regulations are to prescribe required report content, which "must include, without limitation: (A) the name, address, age and ethnicity of the patient; (B) the variant of sickle cell disease; (C) the method of treatment; (D) any other diseases from which the patient suffers; (E) information concerning the usage of and access to health care services by the patient; and (F) if a patient ... dies, his or her age at death and cause of death." The department must protect confidentiality and may provide qualified researchers access under regulation and fees.

For newborns in whom routine screening detects sickle cell trait, the laboratory must notify the newborn’s physician and document the finding in a central registry. The physician (or the laboratory if no physician is identified) must provide parents with information on genetic counseling by a licensed genetic counselor, including a multilingual document listing at least 10 genetic counselors and the public and private payers contracting with each counselor. The commissioner must set up notification systems for parents and for individuals who reach age 18.

For MassHealth enrollees, the Division of Medical Assistance would be required to ensure accessible, integrated care for people with sickle cell disease enrolled in Medicaid managed care or accountable care organizations. Not later than Jan. 1, 2027, contracted plans must implement a sickle cell disease quality strategy that includes member identification within 90 days of enrollment, adequate specialty provider capacity to the extent practicable, care coordination, a training curriculum for primary care providers, and exceptions to prior‑authorization or dispensing limits for pain medications when needed. The division must publish quarterly unduplicated counts of enrollees with sickle cell disease, develop performance measures and attach incentive or penalty provisions to contracts.

The committee report and the text of the bill provide specific definitions, deadlines and reporting requirements; they do not record a floor vote or enactment. The bill was filed Sept. 19, 2025, and appears in the One Hundred and Ninety‑Fourth General Court for consideration.